Valuation: ConvaTec Group

Market Cap 5.62B 4.91B 4.55B 4.17B 7.89B 542B 8.03B 54.21B 21.29B 265B 21.12B 20.65B 913B P/E 2026 *
20.4x
P/E 2027 * 16x
Enterprise Value 6.82B 5.96B 5.51B 5.06B 9.58B 657B 9.74B 65.77B 25.84B 321B 25.62B 25.06B 1,108B EV / Sales 2026 *
2.66x
EV / Sales 2027 * 2.43x
Free-Float
95.19%
Yield 2026 *
2.72%
Yield 2027 * 3.05%
Manager TitleAgeSince
Chief Executive Officer 62 04/08/2025
Director of Finance/CFO 51 04/08/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 71 14/08/2017
Chairman 78 30/09/2019
Director/Board Member 62 02/03/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5.62B
+10.71%+4.69%-24.98%-8.43% 155B
+3.84%+1.42%-6.93%-4.67% 103B
+3.85%+1.83%+3.41%+60.90% 57.7B
+3.26%+6.02%-10.29%-38.34% 42.68B
+4.23%+0.64% - - 33.35B
+7.22%+6.79%-7.31%-43.21% 28.06B
+0.96%+1.34%+61.53%-5.89% 25.36B
-0.85%+4.34%-3.58%-18.66% 21.03B
+4.57%+2.38%-2.85%-3.47% 20.61B
Average +3.78%+2.62%+1.13%-7.72% 54.14B
Weighted average by Cap. +5.82%+2.63%-7.97%-3.83%

Financials

2026 *2027 *
Net sales 2.57B 2.24B 2.07B 1.9B 3.6B 247B 3.67B 24.74B 9.72B 121B 9.64B 9.43B 417B 2.74B 2.39B 2.21B 2.03B 3.84B 264B 3.91B 26.39B 10.37B 129B 10.28B 10.05B 445B
Net income 276M 242M 223M 205M 388M 26.63B 395M 2.66B 1.05B 13B 1.04B 1.01B 44.89B 359M 313M 290M 266M 503M 34.55B 512M 3.46B 1.36B 16.87B 1.35B 1.32B 58.25B
Net Debt 1.2B 1.05B 970M 890M 1.68B 116B 1.71B 11.57B 4.54B 56.45B 4.51B 4.41B 195B 1.03B 904M 836M 767M 1.45B 99.67B 1.48B 9.97B 3.92B 48.67B 3.88B 3.8B 168B
Logo ConvaTec Group
ConvaTec Group Plc specializes in the development, manufacturing and marketing of medical devices and products for ostomy care, wound care, and incontinence. The group also offers perfusion devices. Net sales break down by area of activity as follows: - wound care (30.9%): antimicrobial dressings, occlusive dressings, compression bandages, etc.; - ostomy care (27.7%): skin barriers, one-piece bags, 2-piece appliance bags, urostomy bags, etc.; - incontinence care (22%); - infusion (19.4%). At the end of 2025, the group operated 7 production sites worldwide. Net sales are distributed geographically as follows: Europe (29.6%), North Americas (55.7%) and other (14.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA